Apolipoprotein A-V is a potential target for treating coronary artery disease: evidence from genetic and metabolomic analyses

Apolipoprotein A-V is a potential target for treating coronary artery disease: evidence from genetic and metabolomic analyses

Triglyceride (TG)-lowering LPL variants in combination with genetic LDL-C-lowering variants are associated with reduced risk of coronary artery disease (CAD). Genetic variation in the APOA5 gene encoding apolipoprotein A-V also strongly affects TG levels, but the potential clinical impact and underl...

Full description

Bibliographic Details
Main Authors: Boot, M. (Author), Christodoulides, C. (Author), Dollé, M.E.T (Author), Ibi, D. (Author), Jukema, J.W (Author), Karpe, F. (Author), Koivula, R. (Author), Neville, M.J (Author), Noordam, R. (Author), Rensen, P.C.N (Author), Rosendaal, F.R (Author), van Dijk, K.W (Author)
Format: Article
Language:English
Published: American Society for Biochemistry and Molecular Biology Inc. 2022
Subjects:
cardiovascular disease
clinical data
factorial analysis
hyperlipidemia
LDL genetic variation
lipid-lowering therapy
lipoprotein lipase
lipoproteins
triglycerides
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items